image description

Tag: EULAR

Baricitinib Shows Positive Results for SLE in Phase 2 Study

June 19, 2018 Once-daily oral baricitinib 4 mg was associated with significant clinical improvements compared with placebo in patients with systemic lupus erythematosus┬á(SLE) receiving standard background therapy, according to data presented at the European League Against Rheumatism (EULAR) Congress held in Amsterdam, June 13 to 16, 2018…. A significantly greater percentage of patients in the […] Read More

because the Lupus Research Alliance board of directors funds all administrative and fundraising costs